Insider Selling: Globus Medical (NYSE:GMED) Director Sells $425,000.00 in Stock

Globus Medical, Inc. (NYSE:GMED) Director Ann Rhoads sold 5,000 shares of the firm’s stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $85.00, for a total transaction of $425,000.00. Following the completion of the sale, the director directly owned 35,384 shares in the company, valued at approximately $3,007,640. This trade represents a 12.38% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Globus Medical Trading Down 13.2%

GMED stock opened at $70.67 on Friday. The firm’s 50-day moving average price is $77.20 and its two-hundred day moving average price is $83.18. Globus Medical, Inc. has a 12-month low of $70.39 and a 12-month high of $101.40. The stock has a market capitalization of $9.49 billion, a price-to-earnings ratio of 17.36, a PEG ratio of 1.14 and a beta of 0.98.

Globus Medical (NYSE:GMED) last issued its quarterly earnings data on Thursday, November 5th. The medical device company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.20 by $0.03. The firm had revenue of $763.72 million during the quarter, compared to the consensus estimate of $792.39 million. Globus Medical had a net margin of 17.76% and a return on equity of 14.51%. The company’s quarterly revenue was down .7% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.18 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Equities analysts predict that Globus Medical, Inc. will post 4.99 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on GMED shares. BTIG Research reaffirmed a “neutral” rating on shares of Globus Medical in a research report on Friday. Canaccord Genuity Group cut their price objective on Globus Medical from $115.00 to $105.00 and set a “buy” rating on the stock in a research report on Friday. BMO Capital Markets cut Globus Medical from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $94.00 to $78.00 in a research note on Friday. Wells Fargo & Company upped their target price on Globus Medical from $99.00 to $100.00 and gave the company an “overweight” rating in a report on Friday. Finally, Royal Bank Of Canada decreased their target price on Globus Medical from $115.00 to $85.00 and set an “outperform” rating for the company in a report on Thursday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, Globus Medical presently has a consensus rating of “Moderate Buy” and an average price target of $96.92.

Globus Medical News Roundup

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Third-quarter adjusted earnings were $1.23 per share, ahead of the $1.20 consensus and up from $1.18 a year earlier. Globus also increased its share-repurchase authorization by $500 million, offering potential support for shareholder returns. Third-quarter results and repurchase announcement
• Neutral Sentiment: Analyst views were mixed: Canaccord and Needham cut their price targets but maintained Buy ratings, while Wells Fargo slightly raised its target and kept an Overweight rating. The company is also seeking acquisitions, though the provided report does not detail potential deals. Report on acquisition plans
• Negative Sentiment: Revenue of $763.7 million missed the $792.4 million analyst estimate and declined 0.7% year over year. Full-year 2026 revenue guidance of $3.1 billion is below the roughly $3.2 billion consensus; management cited spine-product launch delays and weak Nevro sales, weighing on expectations despite EPS guidance being broadly in line. Q3 call highlights and outlook
• Negative Sentiment: BMO Capital Markets downgraded GMED from Outperform to Market Perform and cut its price target, adding to concerns about the outlook. Coverage of the stock decline

Hedge Funds Weigh In On Globus Medical

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Sanctuary Advisors LLC lifted its stake in shares of Globus Medical by 2.3% during the 1st quarter. Sanctuary Advisors LLC now owns 6,611 shares of the medical device company’s stock worth $570,000 after purchasing an additional 151 shares during the last quarter. Summitry LLC grew its stake in Globus Medical by 2.6% in the first quarter. Summitry LLC now owns 8,205 shares of the medical device company’s stock valued at $707,000 after purchasing an additional 211 shares during the last quarter. Central Pacific Bank Trust Division grew its stake in Globus Medical by 7.8% in the third quarter. Central Pacific Bank Trust Division now owns 3,057 shares of the medical device company’s stock valued at $229,000 after purchasing an additional 220 shares during the last quarter. Arizona State Retirement System grew its stake in Globus Medical by 0.8% in the second quarter. Arizona State Retirement System now owns 31,077 shares of the medical device company’s stock valued at $2,455,000 after purchasing an additional 252 shares during the last quarter. Finally, Angeles Wealth Management LLC raised its holdings in Globus Medical by 5.0% in the second quarter. Angeles Wealth Management LLC now owns 5,894 shares of the medical device company’s stock worth $466,000 after purchasing an additional 280 shares in the last quarter. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Globus Medical Company Profile